Abuse and neglect can have a long-lasting impact on the health and wellbeing of children and young people. It is important to know how to respond, and the evidence suggests that the following ...

Health inequalities modular update to NICE health technology evaluations: the manual (PMG36) Methods / process manual consultation NICE process and methods 31 January 2025 Highly specialised ...

Suggested remit: To appraise the clinical and cost effectiveness of Vosoritide within its marketing authorisation for treating achondroplasia in children.

A list of downloadable documents created during development.

Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care ...

This procedure can only be done as part of a research study. This is because there is not enough evidence to be sure how well it works. Your healthcare professional should talk to you about the ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

There is a simple discount patient access scheme for tebentafusp. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Tebentafusp (Kimmtrak, Immunocore) is indicated 'as monotherapy for the treatment of human leukocyte antigen (HLA)‑A*02:01-positive adult patients with unresectable or metastatic uveal melanoma'. The ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A. The minutes of each evaluation committee meeting, which include the names of ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. We have a new way of making ...